EUVIMEDEUVIMED entdecken
Crossref

COVID-19 in patients receiving treatment at an outpatient chemotherapy unit

Shiori Kinoshita iD, Masashi Takemoto, Minami Asaoka, Yoko Haraguchi, Tamami Adachi, Shinsuke Iida, Hirokazu Komatsu

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyae129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Shiori Kinoshita und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Nagoya City University, Nagoya, Japan. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During the COVID-19 pandemic period, many patients who required outpatient chemotherapy developed COVID-19, requiring chemotherapy interruption. However, there are no clear guidelines regarding the safe timing for restarting chemotherapy. We conducted a retrospective study to assess when such patients can safely recommence chemotherapy. Of the 40 patients included in this study, 34 restarted anticancer drug therapy after COVID-19 infection. Six patients, four with multiple myeloma, and one each with follicular lymphoma and glioma, remained SARS-CoV-2 antigen positive >20 days after COVID-19 onset. Multiple myeloma patients recorded significantly higher frequencies of SARS-CoV-2 antigen positivity >20 days after COVID-19 onset compared with solid tumor patients, with no significant differences in the frequency of SARS-CoV-2 positivity during 5–20 days from COVID-19 onset between them. According to our data, most solid tumor patients achieved SARS-CoV-2 antigen negativity after 20 days from COVID-19 onset. On the other hand, multiple myeloma patients might need serial antigen tests before restarting anticancer therapy in the outpatient chemotherapy setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2HumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultAntineoplastic AgentsNeoplasmsOutpatientsAged, 80 and overMultiple MyelomaAmbulatory Care

Stichwörter der Autor:innen

COVID-19anticancer drug therapycanceroutpatient chemotherapy unit

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical Oncology, Nagoya City University, Nagoya, Japan.
  • Department of Hematology and Oncology, Nagoya City University, Nagoya, Japan.
  • Department of Pharmacy, Nagoya City University, Nagoya, Japan.
  • Department of Nursing, Nagoya City University, Nagoya, Japan.

ORCID-Profile: Shiori Kinoshita

Zitieren

APA

Kinoshita, S., Takemoto, M., Asaoka, M., Haraguchi, Y., Adachi, T., Iida, S., & Komatsu, H. (2025). COVID-19 in patients receiving treatment at an outpatient chemotherapy unit. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae129

Vancouver

Kinoshita S, Takemoto M, Asaoka M, Haraguchi Y, Adachi T, Iida S, et al. COVID-19 in patients receiving treatment at an outpatient chemotherapy unit. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyae129

BibTeX
@article{Kinoshita2025,
  author = {Kinoshita, Shiori and Takemoto, Masashi and Asaoka, Minami and Haraguchi, Yoko and Adachi, Tamami and Iida, Shinsuke and Komatsu, Hirokazu},
  title = {COVID-19 in patients receiving treatment at an outpatient chemotherapy unit},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyae129}
}
Kostenlos starten →